We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
+35.9%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$6.87B
AUM Growth
+$747M
Cap. Flow
+$514M
Cap. Flow %
7.48%
Top 10 Hldgs %
39.61%
Holding
82
New
19
Increased
22
Reduced
15
Closed
15

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$249M
2
MANE
Veradermics Inc
MANE
+$141M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$118M
4
COAG
Hemab Therapeutics
COAG
+$99.4M
5
UTHR icon
United Therapeutics
UTHR
+$69.6M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$182M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$125M
3
AXSM icon
Axsome Therapeutics
AXSM
+$86.7M
4
IMVT icon
Immunovant
IMVT
+$66.6M
5
BBIO icon
BridgeBio Pharma
BBIO
+$62.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.8%
2 Miscellaneous 1.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GH icon
1
Guardant Health
GH
$23.8B
$509M 7.41%
3,393,312
+55,071
+2% +$5.99M
IMVT icon
2
Immunovant
IMVT
$7.65B
$360M 5.24%
9,341,151
-2,185,820
-19% -$66.6M
GPCR icon
3
Structure Therapeutics
GPCR
$2.69B
$254M 3.7%
4,740,072
+460,224
+11% +$20.4M
PCVX icon
4
Vaxcyte
PCVX
$8.8B
$250M 3.64%
4,300,000
– –
ALNY icon
5
Alnylam Pharmaceuticals
ALNY
$32B
$248M 3.61%
+825,000
New +$249M
MANE
6
Veradermics Inc
MANE
$4.38B
$246M 3.58%
2,000,000
+1,500,000
+300% +$141M
TARS icon
7
Tarsus Pharmaceuticals
TARS
$3.67B
$231M 3.36%
3,666,768
+66,768
+2% +$4.27M
NUVL
8
DELISTED
Nuvalent
NUVL
$220M 3.21%
1,783,322
+406,998
+30% +$43.8M
ALKS icon
9
Alkermes
ALKS
$7.84B
$210M 3.05%
4,000,000
+409,677
+11% +$16M
OCUL icon
10
Ocular Therapeutix
OCUL
$2.24B
$193M 2.81%
19,686,282
– –
BMRN icon
11
BioMarin Pharmaceuticals
BMRN
$12.6B
$189M 2.75%
3,307,481
+2,157,481
+188% +$118M
NRIX icon
12
Nurix Therapeutics
NRIX
$2.61B
$188M 2.73%
7,736,455
+1,391,211
+22% +$23.7M
ORKA
13
Oruka Therapeutics
ORKA
$6.13B
$183M 2.67%
1,926,000
-108,203
-5% -$7.21M
ALMS
14
Alumis Inc
ALMS
$1.06B
$179M 2.6%
6,348,558
-424,037
-6% -$9.87M
IONS icon
15
Ionis Pharmaceuticals
IONS
$7.8B
$174M 2.54%
2,200,000
+250,000
+13% +$18.8M
CMPS
16
Compass Pathways
CMPS
$1.92B
$172M 2.5%
12,161,496
– –
VERA icon
17
Vera Therapeutics
VERA
$2.38B
$172M 2.5%
4,000,000
-106,067
-3% -$3.95M
AXSM icon
18
Axsome Therapeutics
AXSM
$11B
$171M 2.49%
700,000
-400,000
-36% -$86.7M
GMAB icon
19
Genmab
GMAB
$21.1B
$155M 2.26%
5,650,000
+1,986,750
+54% +$52.8M
MLTX icon
20
MoonLake Immunotherapeutics
MLTX
$1.03B
$136M 1.98%
6,999,025
+590,162
+9% +$10.7M
COAG
21
Hemab Therapeutics
COAG
$1.9B
$132M 1.93%
+3,602,093
New +$99.4M
TNGX icon
22
Tango Therapeutics
TNGX
$4.06B
$131M 1.91%
4,200,000
+1,450,000
+53% +$35.8M
DFTX
23
Definium Therapeutics
DFTX
$5.01B
$129M 1.88%
2,750,000
-250,000
-8% -$6.18M
GRAL
24
GRAIL Inc
GRAL
$3.45B
$125M 1.82%
1,834,944
+112,147
+7% +$6.6M
BCAX
25
Bicara Therapeutics
BCAX
$1.51B
$122M 1.77%
4,100,000
+37,500
+0.9% +$837K
1
2 3 4

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Deep Track Capital held 82 positions worth $6.87B, up 12% from $6.12B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Deep Track Capital deployed $514M of net new capital in Q2 2026, opening 19 new positions and adding to 22 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 825,000 shares worth $248M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 79% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $86.7M trimmed.

  • Deep Track Capital's largest Q2 2026 buy was Alnylam Pharmaceuticals: 825,000 shares worth $248M.
  • Deep Track Capital added most to Veradermics Inc in Q2 2026, an estimated $141M increase.
  • Deep Track Capital's biggest Q2 2026 reduction was Axsome Therapeutics, cutting an estimated $86.7M.
  • Deep Track Capital fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $182M.
  • Deep Track Capital's ten largest holdings make up 40% of its $6.87B portfolio in Q2 2026.
  • Deep Track Capital opened 19 new positions and closed 15 in Q2 2026.
  • Deep Track Capital's portfolio value rose 12% quarter-over-quarter to $6.87B.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.